--- title: "Weekly Recap | NVO 2X Long ETF +0.82%, most brokers rate the stock hold" type: "News" locale: "en" url: "https://longbridge.com/en/news/302942890.md" description: "The NVO 2X Long ETF gained 0.82% this week, closing at $9.84 versus $9.76 the prior Friday. The S&P 500 slipped 0.47%, leaving this ETF about 1.29 percentage points ahead. The week was choppy but biased higher: Monday opened weak and touched $9.53, Tuesday jumped to $10.02 on strong volume, midweek traded between $9.88 and $10.08, Thursday peaked at $10.22, and Friday pulled back to $9.84." datetime: "2026-10-24T04:39:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302942890.md) - [en](https://longbridge.com/en/news/302942890.md) - [zh-HK](https://longbridge.com/zh-HK/news/302942890.md) generator: "portal-rs" --- # Weekly Recap | NVO 2X Long ETF +0.82%, most brokers rate the stock hold ## The Week The NVO 2X Long ETF gained 0.82% this week, closing at $9.84 versus $9.76 the prior Friday. The S&P 500 slipped 0.47%, leaving this ETF about 1.29 percentage points ahead. The week was choppy but biased higher: Monday opened weak and touched $9.53, Tuesday jumped to $10.02 on strong volume, midweek traded between $9.88 and $10.08, Thursday peaked at $10.22, and Friday pulled back to $9.84. ## Novo Nordisk AS This Week Underlying Novo Nordisk AS (NVO) rose 0.57% to close at $39.05, up from $38.83 the prior Friday. The stock followed a similar choppy upward path: Monday dipped to $38.35, Tuesday surged to $39.35 on heavy volume, and the next three sessions held near $39. The weekly high was $39.765 on Thursday before easing to $39.05 on Friday. ## Leverage & Decay This ETF aims to deliver 2x the daily move in Novo Nordisk AS, not 2x the weekly return. NVO rose 0.57% this week, implying a theoretical leveraged gain of about 1.14%, but the ETF gained only 0.82%—a gap of around 0.32 percentage points. That gap comes from daily rebalancing: the fund resets its exposure to 2x each day, so when the underlying swings back and forth, compounded daily returns drift from the theoretical figure. Decay is modest in a straight trend but widens in choppy conditions; holding for a week is not the same as a clean 2x weekly outcome. ## Novo Nordisk AS News Novo Nordisk’s week was dominated by obesity and diabetes pipeline news. On Tuesday, an analysis showed CagriSema helped women lose 25% of body weight on average; NVO shares climbed 2% the next day. Broader industry coverage highlighted major drugmakers turning to China for licensing deals and the pharma sector doubling down on AI to cut costs. After Friday’s close, the FDA approved Awiqli as the first once-weekly insulin for paediatric type 2 diabetes. The company also began a share repurchase programme, while Carnegie Investment Counsel reduced its NVO stake by about 48,696 shares. ## Novo Nordisk AS — Analyst Ratings Fourteen institutions cover Novo Nordisk AS: three rate it strong buy, ten hold, and one sell. The consensus rating is hold, with a consensus target of roughly $45.27, about 15.93% above the current $39.05 price. Targets range from $39.90 to $62.03, underscoring wide disagreement. Within the pharmaceutical industry, Novo Nordisk ranks 17th among 203 companies by rating, against an industry average of six and a median of five covering firms. ## The Week Ahead The next earnings date is 4 November 2026, when Novo Nordisk reports Q3 2026 results before the open, with consensus at $0.7929 EPS and $11.1 billion revenue. On the macro side, Dallas Fed manufacturing data lands on 26 October, followed by US housing, durable goods and consumer confidence prints on 27 October. For a leveraged product, the key is NVO’s volatility into earnings rather than the macro releases themselves. ## In Short The ETF beat the S&P 500 by about 1.29 percentage points this week, while NVO rose 0.57% and the leveraged product lost roughly 0.32 percentage points of theoretical return to daily rebalancing. On the analyst side, the consensus rating is hold, with the target about 15.93% above spot and targets spread across a roughly $22 range—a sign of wide disagreement. The latest session showed net selling across large, medium and small lots, suggesting weak short-term flow. The next test is the 3 November earnings report and whether pre-print volatility widens the leverage decay. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md) ## Related News & Research - [Lilly’s Foundayo wins EMA panel backing for obesity and type 2 diabetes](https://longbridge.com/en/news/302243582.md) - [Novo Nordisk A/S $NVO Stock Sold by Eastern Bank](https://longbridge.com/en/news/301000491.md) - [Alphabet Has $514 Billion in Cloud Orders. Here’s What Matters More Than That Number on Oct. 28.](https://longbridge.com/en/news/303058851.md) - [Micron Technology Inc Stock (MU) Moved Up by 3.23% on Oct 26: A Full Analysis](https://longbridge.com/en/news/303106212.md) - [Tesla-SpaceX Merger Stands at 80%-90% Chance, Dan Ives' $500 Price Tag Explains Why](https://longbridge.com/en/news/303112286.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**